Reduce tremor while preserving speech

Trial ID
NCT04650932
Official Title
Dual Frequency, Dual Region Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
Goal
Reduce tremor while preserving speech
Phase
NA
Status
RECRUITING
Sponsor
University of California, Davis
Study Type
INTERVENTIONAL
Enrollment
10 participants
Conditions
Parkinson Disease
Interventions
Deep brain stimulation

Plain-Language Summary

The goal is to test whether giving different electrical frequencies to the upper and lower parts of the subthalamic nucleus can better control tremor, slowness, and stiffness while reducing cognitive or speech side effects. The approach uses the already-implanted Boston Scientific Vercise DBS system to send targeted pulses to dorsal and ventral STN contacts, changing abnormal brain circuit activity that causes motor symptoms; it does not replace levodopa but can change how well motor control responds and may allow medication adjustments. Looking for adults 18 and older with idiopathic, advanced Parkinson's who already have the Vercise system implanted for at least 3 months with bilateral dorsal STN leads reaching the ventral STN, who can do cognitive testing in English and meet simple MoCA and depression score cutoffs.

Locations

  • UC Davis Health, Sacramento, California, United States

Frequently Asked Questions

What is this trial testing?
This trial is studying Deep brain stimulation. The goal is to test whether giving different electrical frequencies to the upper and lower parts of the subthalamic nucleus can better control tremor, slowness, and stiffness while reducing cognitive or speech side effects. The approach uses the already-implanted Boston Scientific Vercise DBS system to send targeted pulses to dorsal and ventral STN contacts, changing abnormal brain circuit activity that causes motor symptoms; it does not replace levodopa but can change how well motor control responds and may allow medication adjustments. Looking for adults 18 and older with idiopathic, advanced Parkinson's who already have the Vercise system implanted for at least 3 months with bilateral dorsal STN leads reaching the ventral STN, who can do cognitive testing in English and meet simple MoCA and depression score cutoffs.
Who can participate?
Participants must be at least 18 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 3 years and 8 months.

View on ClinicalTrials.gov